TheStreet Ratings

10 Best Biotech Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for

Biotechnology News

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
3/28/17 8:45PM
Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.
3/28/17 7:00PM
Regeneron and Sanofi will launch Dupixent with a gross sticker price of $37,000 per year, before insurance discounts and rebates.
3/28/17 4:16PM
The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.
3/27/17 4:07PM
The XBiotech drug, Xilonix, had no effect on the size of colon cancer tumors with zero complete or partial responses reported in the phase III study.
3/27/17 1:18PM
Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.
3/27/17 8:07AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
3/24/17 8:34AM
Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
3/20/17 7:30AM
Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
3/17/17 10:38AM
PTC Therapeutics already sells a drug for Duchenne muscular dystrophy that does not work. Now, the drug maker is buying a second, approved Duchenne drug mired in a price-gouging controversy.
3/16/17 10:54AM
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
3/14/17 3:43PM
The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.
3/14/17 9:59AM
Aurinia executives don't manage the business to serve the interest of traders and their desire to flip the stock for a few bucks' profit.
3/14/17 9:01AM
Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.
3/13/17 12:51PM
Gottlieb is the preferred FDA Commissioner pick of the drug industry and healthcare investors.
3/10/17 2:22PM